Corcept Therapeutics (CORT.O) said Thursday its experimental ovarian cancer drug met its primary survival endpoint in a Phase 3 trial, with shares jumping 25% in pre-market trading 1.
The positive results for relacorilant could position the company to seek regulatory approval for platinum-resistant ovarian cancer, a market with limited treatment options.
Key Takeaways
- Phase 3 ROSELLA trial met dual primary endpoints successfully
- 35% reduction in death risk versus standard treatment
- Median survival improved to 16 months from 11.9 months
Trial Results and Market Impact
The 381-patient international ROSELLA trial showed patients treated with relacorilant plus nab-paclitaxel achieved a median overall survival of 16.0 months compared to 11.9 months for those receiving nab-paclitaxel alone 2. The combination demonstrated a 35% reduction in the risk of death 3.
Both dual primary endpoints – progression-free survival and overall survival – were met in the study 4. The trial evaluated relacorilant, a selective glucocorticoid receptor antagonist, in patients with platinum-resistant ovarian cancer.
Regulatory Pathway Forward
The positive Phase 3 results provide Corcept with the data needed to pursue regulatory approval from the FDA and other global health authorities. Platinum-resistant ovarian cancer represents a significant unmet medical need with few effective treatment options.
Corcept’s existing approved drug, Korlym (mifepristone), is currently marketed for Cushing’s syndrome. The company has been developing relacorilant as a potentially safer and more effective glucocorticoid receptor antagonist across multiple indications.
Competitive Landscape
The ovarian cancer treatment market has seen limited innovation in recent years, particularly for platinum-resistant cases. Current standard treatments include chemotherapy agents like nab-paclitaxel, but median survival outcomes remain poor.
Relacorilant’s mechanism of action differs from traditional chemotherapy by targeting the glucocorticoid receptor pathway, which can contribute to cancer progression and treatment resistance.
Financial Implications
The successful trial outcome significantly enhances Corcept’s commercial prospects and validates its glucocorticoid receptor antagonist platform. The company’s market capitalization has grown substantially on the positive news, reflecting investor confidence in the regulatory and commercial potential.
Analysts will likely reassess revenue projections for relacorilant based on the trial’s strong survival benefit and the size of the platinum-resistant ovarian cancer patient population.
Not investment advice. For informational purposes only.
References
1(January 22, 2026). “Corcept’s ROSELLA Phase 3 Trial Meets Overall Survival Endpoint, Shares Jump 25% In Pre-Market”. RTTNews. Retrieved January 22, 2026.
2(January 22, 2026). “Corcept Therapeutics stock soars after cancer drug meets survival endpoint”. Investing.com. Retrieved January 22, 2026.
3(January 22, 2026). “Corcept posts trial win for ovarian cancer therapy”. Seeking Alpha. Retrieved January 22, 2026.
4(January 22, 2026). “Overall Survival Primary Endpoint Met in Corcept’s Pivotal Phase 3 ROSELLA Trial”. Business Wire. Retrieved January 22, 2026.